B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
about
The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells.Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib.The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.Mitochondrial ATF2 translocation contributes to apoptosis induction and BRAF inhibitor resistance in melanoma through the interaction of Bim with VDAC1.Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas.Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities.Suppression of microphthalmia-associated transcription factor, but not NF-kappa B sensitizes melanoma specific cell death.
P2860
Q30837718-BC65D7A0-1D30-4856-A968-909295FFC8C2Q33433902-8C5866DB-7104-4BE4-B3F8-32E69E7D570EQ36020990-76444021-4708-4B47-A2EA-EFA16F8B6D4DQ36546659-1A3E9974-401E-41F1-9819-AA09021C5ACAQ38708463-DE4138E8-5B65-43FD-A6F5-CF408997B5D7Q39191984-3F95CBB2-E583-43AD-A645-7990002F8005Q50794958-52455C72-4BB9-4C68-BB38-F7DC11257A4E
P2860
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
B-Raf inhibitor vemurafenib in ...... e of malignant melanoma cells.
@en
type
label
B-Raf inhibitor vemurafenib in ...... e of malignant melanoma cells.
@en
prefLabel
B-Raf inhibitor vemurafenib in ...... e of malignant melanoma cells.
@en
P2093
P2860
P356
P1433
P1476
B-Raf inhibitor vemurafenib in ...... se of malignant melanoma cells
@en
P2093
Andrea Krumm
Bernd Kaina
Carmen Loquai
Markus Christmann
Olivier Jérôme Switzeny
Stephanie Merz
P2860
P304
12607-12620
P356
10.18632/ONCOTARGET.2610
P407
P577
2014-12-01T00:00:00Z